F11 and acute coronary syndrome: In high-risk clinical settings such as orthopedic surgery, end-stage renal disease, atrial fibrillation, and selected acute coronary syndrome cohorts, FXI inhibitors have shown efficacy that appears comparable to conventional anticoagulation, accompanied by lower bleeding rates, particularly among patients with elevated hemorrhagic risk or multiple comorbidities [63,67,68].